Sigma Aldrich Acquires Semiconductor Chemicals Manufacturer Epichem Group

Sigma-Aldrich Corporation announced today that it has acquired all of the outstanding shares of Epichem Group Limited of Bromborough, United Kingdom, to expand its SAFC Hitech business offering. The purchase price of $60 million was paid in cash.

The acquisition of Epichem's $40 million in annual revenues is expected to help Sigma-Aldrich achieve its growth goals in key high technology markets over the next several years and will be neutral to mildly accretive to earnings in 2007, with no significant initial charges.

Barry Leese, Managing Director of Epichem, its majority equity holder and one of the founders of the company has been appointed President of the SAFC Hitech business segment. Epichem management and employees will remain in place.

As the consumer market continually demands faster, higher-performance semiconductor devices with increased energy efficiencies, technology demands have placed materials and materials knowledge at the forefront of product innovation, with chemistry playing an increasingly important role in new product development. Epichem, focused on supplying high-purity chemicals to the electronics and photovoltaic markets, joins its proven expertise in the development of new molecules and innovative customer/partner collaborative processes for the semiconductor markets with SAFC's historic expertise in novel chemistry development and manufacturing in creating a powerful new entity.

"Epichem's strong product portfolio and solid relationships with key end users and equipment suppliers brings important new global customer relationships to SAFC Hitech," commented Frank Wicks, President of SAFC. "Their experienced team, capabilities and contacts combined with SAFC's industry-leading development, manufacturing, global footprint and financial strength will allow us to provide the electronics industry with even better specialized, high-quality materials that meet customer demands."

"The synergy created through this acquisition is a great fit for both organizations," said Leese. "This venture pairs solid development and commercial manufacturing capabilities with a robust product portfolio and customer-centric collaborative R&D process, strongly positioning us to become a leading supplier and developer of new materials for the market."

"The semiconductor industry continuously demands fresh materials and architectures to improve power, performance and density to deliver next- generation advanced technology products," said President Arvind Sodhani, Intel Capital. "Epichem is an innovator in semiconductor materials and the combination with Sigma-Aldrich brings together complementary strengths to support this market segment." Intel Capital was the sole investor in financing Epichem in October 2005.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sigma-Aldrich. (2019, March 02). Sigma Aldrich Acquires Semiconductor Chemicals Manufacturer Epichem Group. AZoM. Retrieved on July 21, 2024 from https://www.azom.com/news.aspx?newsID=7767.

  • MLA

    Sigma-Aldrich. "Sigma Aldrich Acquires Semiconductor Chemicals Manufacturer Epichem Group". AZoM. 21 July 2024. <https://www.azom.com/news.aspx?newsID=7767>.

  • Chicago

    Sigma-Aldrich. "Sigma Aldrich Acquires Semiconductor Chemicals Manufacturer Epichem Group". AZoM. https://www.azom.com/news.aspx?newsID=7767. (accessed July 21, 2024).

  • Harvard

    Sigma-Aldrich. 2019. Sigma Aldrich Acquires Semiconductor Chemicals Manufacturer Epichem Group. AZoM, viewed 21 July 2024, https://www.azom.com/news.aspx?newsID=7767.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.